top of page
  • pharmaserviceinc

Regulatory Landscape for In-House IVDs in Australia

In the dynamic world of medical diagnostics, Australian laboratories engaged in the manufacture of in-house in vitro diagnostic medical devices (IVDs) face rigorous regulatory requirements to ensure the safety, quality, and performance of their products. These regulations, which commenced on 1 July 2010, are crucial for legally supplying these in-house IVDs within Australia. This blog post will delve into the essential aspects of this regulatory framework and provide guidance for laboratories navigating these requirements.


Understanding In-House IVDs in Australia


In-house IVDs are pathology tests developed or modified within a laboratory to test human samples, assisting in clinical diagnosis or clinical management decisions. Unlike commercially supplied IVDs, in-house IVDs are crafted within the confines of the laboratory or its network and are used exclusively within that environment.


Key Features of the IVD Regulatory Framework


The IVD regulatory framework is structured to ensure that all in-house IVDs in Australia meet stringent standards of quality, safety, and performance. Here are its main features:


  1. Essential Principles: IVDs must adhere to a set of Essential Principles that cover the quality, safety, and performance of the devices.

  2. Risk-Based Classification: The regulation employs a risk-based classification scheme, which mandates varying levels of regulatory oversight based on the device's class.

  3. Conformity Assessment Procedures: Depending on the risk classification, manufacturers can choose from different conformity assessment procedures to demonstrate compliance with the Essential Principles.

  4. Compliance with Recognized Standards: Adhering to recognized standards is a primary method for proving that the Essential Principles and conformity assessment procedures have been satisfied.

  5. Post-Market Activities: This includes ongoing monitoring and adverse event reporting to ensure continued compliance and safety after the device is on the market.


Roles of Key Bodies

The regulatory requirements are enforced with the collaboration of several key bodies:


  • Therapeutic Goods Administration (TGA): The primary regulatory authority overseeing the compliance of in-house IVDs.

  • National Association of Testing Authorities (NATA): Works alongside TGA to ensure laboratories meet accreditation standards.

  • Laboratories: Must maintain robust quality management systems and comply with all regulatory requirements.


The Memorandum of Understanding (MoU) between NATA and TGA clarifies the interaction and responsibilities of both organizations in regulating in-house IVDs.


Regulatory Compliance for In-House IVDs in Australia

Laboratories must ensure that their in-house IVDs in Australia comply with the relevant standards and procedures. Here's a breakdown of how they can achieve this:


  1. Accreditation: Laboratories must be accredited by NATA, either as a medical testing laboratory to ISO 15189 standards or a non-medical testing laboratory to ISO 17025 standards, depending on their specific operations.

  2. Documentation and Validation: All modifications and developments of IVDs must be thoroughly documented and validated to ensure safety and effectiveness. This includes assembling, processing, and packaging components, and clearly assigning the intended purpose through provided information.

  3. Notification and Reporting: Laboratories are required to notify the TGA of their class 1-3 in-house IVDs and re-notify when new IVDs are introduced. This involves submitting detailed information via a standardized notification template.

  4. Conformity Assessment: For class 4 in-house IVDs, laboratories must include these devices in the Australian Register of Therapeutic Goods (ARTG) and comply with stringent conformity assessment procedures.


Pathways for Class 4 In-House IVDs

For class 4 in-house IVDs, laboratories have two pathways to achieve regulatory compliance:

  1. TGA Conformity Assessment Certificates: Laboratories without valid NATA accreditation or a TGA manufacturing licence can obtain TGA conformity assessment certificates, which include a Quality Management System (QMS) certificate and a Design Examination (DE) certificate for each class 4 IVD.

  2. Using Existing Accreditations: Laboratories with existing NATA accreditation to ISO 15189 or a TGA manufacturing licence can apply directly for inclusion of their class 4 in-house IVDs in the ARTG without needing separate TGA conformity assessment certificates.


Conclusion

Compliance with the regulatory framework for in-house IVDs in Australia is essential for ensuring the safety and reliability of diagnostic tests. Laboratories must diligently adhere to accreditation standards, maintain thorough documentation, and participate in ongoing monitoring and reporting activities. By following these guidelines, laboratories can confidently develop and supply in-house IVDs that meet the highest standards of quality and performance.


Find the official document attached Here!


TGA_Regulatory requirements for in-house IVDs
.pdf
Download PDF • 664KB


In-House IVDs in Australia
In-House IVDs in Australia


0 views0 comments

Comentarios


bottom of page